Financial information

Summary of consolidated statements of financial position
(Unit : one million won, as of K-IFRS separate financial statements )
Category 2022 2023 2024 2025
Current assets 425,457 378,091 306,413 296,512
Non-current assets 202,516 266,947 298,185 308,762
Total assets 627,973 645,039 604,599 605,273
Current liabilities 380,131 286,927 208,615 209,159
Non-current liabilities 22,083 92,671 66,497 26,745
Total liabilities 402,214 379,598 275,112 235,904
Capital 59,418 61,100 62,253 62,253
Capital surplus 104,358 102,769 101,616 101,616
Other Capital Components -11,065 -11,325 -12,076 -21,616
Accumulated Other Comprehensive Income -1,487 -133 13,570 12,546
Non-Controlling Interest -14,595 - 0 0
Retained Earnings 89,130 113,029 164,123 214,569
Total Equity 225,759 265,440 329,487 369,370
Summary of separate financial statements
(Unit : one million won, as of K-IFRS separate financial statements )
Category 2022 2023 2024 2025
Current assets 361,770 351,056 308,105 275,803
Non-current assets 207,046 269,448 274,540 320,133
Total assets 568,816 620,504 582,645 595,935
Current liabilities 306,448 254,761 206,097 193,635
Non-current liabilities 13,474 90,576 39,026 24,550
Total liabilities 319,922 345,337 245,123 218,185
Capital 59,418 61,100 62,253 62,253
Capital surplus 104,413 102,732 101,578 101,578
Other Capital Components -11,065 -11,325 -12,076 -21,616
Accumulated Other Comprehensive Income -70 -70 13,812 13,437
Retained Earnings 96,197 122,731 171,953 222,098
Total Equity 248,894 275,167 337,522 377,750

Copyright © JW Pharmaceutical,. All rights reserved